Company Overview of Provista Diagnostics, Inc.
Provista Diagnostics, Inc. develops and commercializes blood-based diagnostic, prognostic, and monitoring tests to address the women's cancers. It designs proteomic tests to detect the presence or absence of cancer and the risk of developing cancer in the future, and perform the tests in its clinical laboratory. The company develops blood-based molecular diagnostic tests to address the breast, ovarian, endometrial, and human papillomavirus (HPV) associated cancers. Its products include Videssa Breast, a biomarker panel along with patient data and statistical modeling to improve standard of care in women with suspicious breast lesions; Videssa Ovarian, a blood-based biomarker assay to aid in ...
55 Broad Street
New York, NY 10004
Founded in 2007
Key Executives for Provista Diagnostics, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2015.
Provista Diagnostics, Inc. Key Developments
Provista Diagnostics Inc. Announces Management Changes
Apr 6 16
Provista Diagnostics Inc. announced that it has promoted Uriel Kusiatin, to Chief Financial Officer and Kelly Gordon to Vice President of Research and Development. Additionally, the company has filled senior positions on the rapidly expanding commercial team, with Doug Bradley, joining as Vice President of Global Marketing, and Wendy Ross Morray joining as Senior Director of Reimbursement. Mr. Kusiatin began his career at Deloitte and has dedicated the past 25 years to helping companies solve significant business and financial challenges. He has overseen strategy development, operational execution and financial management at numerous companies in the life sciences industry. He has also advised large international pharmaceutical, biotech and medical device companies, as well as start-up companies. Dr. Gordon joined the company in 2015 as Director of Clinical Development. Prior to the company, Gordon served as the CDx Regulatory Affairs Manager for Roche Tissue Diagnostics where she was the contact for a cross-functional team of biostatisticians, clinical affairs managers, data managers, development scientists, manufacturing personnel, marketing managers, pathologists, project managers and quality engineers and managed companion diagnostics projects for oncology drugs at all stages of development. Mr. Bradley joins the company from Caris Life Sciences, where he served as Vice President of Marketing. Prior to Caris, he held the position of Executive Vice President of Global Marketing at Agendia, a molecular diagnostic company that develops and markets genomic assays for early stage breast cancer. He brings extensive experience in marketing in an array of diagnostics, medical devices, and capital equipment for businesses ranging from Fortune 500 market leaders to start-up companies and high-growth enterprises. Ms. Morray joins the company from Prometheus Laboratories Inc., where she served as the Director of Coding and Reimbursement. She has more than 35 years of experience managing coverage and reimbursement strategy, including consulting to laboratories developing and using new technologies. In this capacity, she has advised on reimbursement models given evolving industry and regulatory trends and has helped develop patient assistance programs.
Provista Diagnostics, Inc. Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016
Mar 12 16
Provista Diagnostics, Inc. Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016. Venue: Hilton Zurich Airport Hotel, 27 Belsize Lane, London | NW3 5AS, United Kingdom. Presentation Date & Speakers: Mar-15-2016, David Reese, President and CEO.
Provista Diagnostics, Inc. Appoints Susan Gross as Chief Medical Officer
Mar 1 16
Provista Diagnostics, Inc. has appointed Susan Gross, M.D., as Chief Medical Officer. In this role, Dr. Gross will oversee and guide the continued clinical progress of the company's pipeline diagnostics and identify new diagnostic approaches for development. She is a professor of Clinical Obstetrics & Gynecology and Women's Health, Pediatrics and Genetics at the Albert Einstein College of Medicine in New York City, and she has contributed to national guideline and policy development. Dr. Gross joins Provista from Natera where she served as the Chief Medical Officer, overseeing the development of the company's prenatal screening tests. Dr. Gross is also the founding director of Einstein's Program for Jewish Genetic Health and founder of the Human Genetics Laboratory at Jacobi Medical Center, which was developed to provide underserved women with equal access to prenatal genetic services.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 8, 2016
July 23, 2015